These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 23788635)

  • 1. Residual prostate cancer cells after docetaxel therapy increase the tumorigenic potential via constitutive signaling of CXCR4, ERK1/2 and c-Myc.
    Hatano K; Yamaguchi S; Nimura K; Murakami K; Nagahara A; Fujita K; Uemura M; Nakai Y; Tsuchiya M; Nakayama M; Nonomura N; Kaneda Y
    Mol Cancer Res; 2013 Sep; 11(9):1088-100. PubMed ID: 23788635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells.
    Karanika S; Karantanos T; Kurosaka S; Wang J; Hirayama T; Yang G; Park S; Golstov AA; Tanimoto R; Li L; Thompson TC
    Mol Cancer; 2015 Jun; 14():122. PubMed ID: 26084402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy.
    Domanska UM; Timmer-Bosscha H; Nagengast WB; Oude Munnink TH; Kruizinga RC; Ananias HJ; Kliphuis NM; Huls G; De Vries EG; de Jong IJ; Walenkamp AM
    Neoplasia; 2012 Aug; 14(8):709-18. PubMed ID: 22952424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells.
    Gupta S; Weston A; Bearrs J; Thode T; Neiss A; Soldi R; Sharma S
    Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):349-357. PubMed ID: 27349498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AMD3100 inhibits epithelial-mesenchymal transition, cell invasion, and metastasis in the liver and the lung through blocking the SDF-1α/CXCR4 signaling pathway in prostate cancer.
    Zhu WB; Zhao ZF; Zhou X
    J Cell Physiol; 2019 Jul; 234(7):11746-11759. PubMed ID: 30537000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models.
    Gravina GL; Mancini A; Muzi P; Ventura L; Biordi L; Ricevuto E; Pompili S; Mattei C; Di Cesare E; Jannini EA; Festuccia C
    Prostate; 2015 Sep; 75(12):1227-46. PubMed ID: 26073897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proinflammatory CXCL12-CXCR4/CXCR7 Signaling Axis Drives Myc-Induced Prostate Cancer in Obese Mice.
    Saha A; Ahn S; Blando J; Su F; Kolonin MG; DiGiovanni J
    Cancer Res; 2017 Sep; 77(18):5158-5168. PubMed ID: 28687617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CXCR4 expression in prostate cancer progenitor cells.
    Dubrovska A; Elliott J; Salamone RJ; Telegeev GD; Stakhovsky AE; Schepotin IB; Yan F; Wang Y; Bouchez LC; Kularatne SA; Watson J; Trussell C; Reddy VA; Cho CY; Schultz PG
    PLoS One; 2012; 7(2):e31226. PubMed ID: 22359577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CXCL12/CXCR4 signaling counteracts docetaxel-induced microtubule stabilization via p21-activated kinase 4-dependent activation of LIM domain kinase 1.
    Bhardwaj A; Srivastava SK; Singh S; Arora S; Tyagi N; Andrews J; McClellan S; Carter JE; Singh AP
    Oncotarget; 2014 Nov; 5(22):11490-500. PubMed ID: 25359780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular complexity of taxane-induced cytotoxicity in prostate cancer cells.
    Mang J; Merkle K; Heller M; Schüler J; Tolstov Y; Li J; Hohenfellner M; Duensing S
    Urol Oncol; 2017 Jan; 35(1):32.e9-32.e16. PubMed ID: 27692847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells.
    Jung MJ; Rho JK; Kim YM; Jung JE; Jin YB; Ko YG; Lee JS; Lee SJ; Lee JC; Park MJ
    Oncogene; 2013 Jan; 32(2):209-21. PubMed ID: 22370645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of PTEN permits CXCR4-mediated tumorigenesis through ERK1/2 in prostate cancer cells.
    Chetram MA; Odero-Marah V; Hinton CV
    Mol Cancer Res; 2011 Jan; 9(1):90-102. PubMed ID: 21076047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CXCR4, a potential predictive marker for docetaxel sensitivity in gastric cancer.
    Xie L; Wei J; Qian X; Chen G; Yu L; Ding Y; Liu B
    Anticancer Res; 2010 Jun; 30(6):2209-16. PubMed ID: 20651371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Mechanism Mediating Cytotoxic Activity of Cabazitaxel in Docetaxel-resistant Human Prostate Cancer Cells.
    Watanabe H; Kawakami A; Sato R; Watanabe K; Matsushita Y; Miyake H
    Anticancer Res; 2021 Aug; 41(8):3753-3758. PubMed ID: 34281834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PIM1 kinase as a target in prostate cancer: roles in tumorigenesis, castration resistance, and docetaxel resistance.
    Holder SL; Abdulkadir SA
    Curr Cancer Drug Targets; 2014; 14(2):105-14. PubMed ID: 24274399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction between docetaxel resistance and castration resistance in prostate cancer: implications of Twist1, YB-1, and androgen receptor.
    Shiota M; Kashiwagi E; Yokomizo A; Takeuchi A; Dejima T; Song Y; Tatsugami K; Inokuchi J; Uchiumi T; Naito S
    Prostate; 2013 Sep; 73(12):1336-44. PubMed ID: 23775496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of claspin promotes docetaxel resistance and is associated with prostate-specific antigen recurrence in prostate cancer.
    Babasaki T; Sentani K; Sekino Y; Kobayashi G; Thang Pham Q; Katsuya N; Akabane S; Taniyama D; Hayashi T; Shiota M; Oue N; Teishima J; Matsubara A; Yasui W
    Cancer Med; 2021 Aug; 10(16):5574-5588. PubMed ID: 34240817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer.
    Kroon J; Puhr M; Buijs JT; van der Horst G; Hemmer DM; Marijt KA; Hwang MS; Masood M; Grimm S; Storm G; Metselaar JM; Meijer OC; Culig Z; van der Pluijm G
    Endocr Relat Cancer; 2016 Jan; 23(1):35-45. PubMed ID: 26483423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1.
    Alshaker H; Wang Q; Kawano Y; Arafat T; Böhler T; Winkler M; Cooper C; Pchejetski D
    Oncotarget; 2016 Dec; 7(49):80943-80956. PubMed ID: 27821815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PrLZ increases prostate cancer docetaxel resistance by inhibiting LKB1/AMPK-mediated autophagy.
    Zeng J; Liu W; Fan YZ; He DL; Li L
    Theranostics; 2018; 8(1):109-123. PubMed ID: 29290796
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.